

Robert B Den

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6536402/publications.pdf>

Version: 2024-02-01

143
papers

6,883
citations

46918

47
h-index

69108

77
g-index

145
all docs

145
docs citations

145
times ranked

9365
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. <i>European Urology</i> , 2022, 81, 325-330.	0.9	7
2	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 5.e1-5.e13.	0.8	2
3	Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 294-303.	0.4	19
4	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022, 40, 19-26.	0.2	7
5	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 320-329.	3.2	46
6	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
7	Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. , 2021, 5, 50-61.		1
8	A comparative study of PCS and PAM50 prostate cancer classification schemes. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 733-742.	2.0	14
9	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. <i>Cancer Discovery</i> , 2021, 11, 2334-2353.	7.7	40
10	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
11	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	2.0	50
12	Impact of Decipher on use of postoperative radiotherapy: Individual patient analysis of two prospective registries. <i>BJUI Compass</i> , 2021, 2, 267-274.	0.7	7
13	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 136-143.	2.0	36
14	Feasibility and Impact of Emotional Intelligence Evaluation in Radiation Oncology Residency Interviews. <i>Journal of the American College of Radiology</i> , 2020, 17, 289-292.	0.9	3
15	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 295-302.	2.0	30
16	Increased expression of desmin and vimentin reduces bladder smooth muscle contractility via JNK2. <i>FASEB Journal</i> , 2020, 34, 2126-2146.	0.2	5
17	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1474-1494.	0.8	141
18	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2

#	ARTICLE	IF	CITATIONS
19	A phase IB clinical trial of 15ÂGy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2020, 19, 282-289.	0.2	6
20	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
21	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e1-848.e7.	0.8	3
22	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	0.8	170
23	Prognostic value of the SPOP mutant genomic subclass in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 418-422.	0.8	8
24	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58
25	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
26	Avoidance sectors to reduce dosimetric impact of an irreproducible pannus on setup uncertainty in prostate SBRT VMAT: A case study. <i>Medical Dosimetry</i> , 2019, 44, 179-182.	0.4	2
27	The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2019, 18, 209-217.	1.0	6
28	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , 2019, 2, 589-596.	2.6	19
29	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019, 9, 1538-1555.	7.7	88
30	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019, 10, 4358.	5.8	109
31	The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	22
32	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 401-413.e6.	7.7	127
33	Patient-Centered Oncology or Population-Centered Oncologyâ€”Which Do We Want, and Which Tradeoffs Are We Willing To Accept?. <i>Oncologist</i> , 2019, 24, 288-290.	1.9	0
34	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment NaÃve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	3.2	74
35	Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. <i>Frontiers in Oncology</i> , 2019, 9, 1273.	1.3	3
36	Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 399-406.	0.6	34

#	ARTICLE	IF	CITATIONS
37	Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 292-302.	2.0	10
38	Tumor cell heterogeneity and resistance; report from the 2018 Coffey&Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2019, 79, 244-258.	1.2	13
39	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	3.0	142
40	NF- κ B and GATA-Binding Factor 6 Repress Transcription of Caveolins in Bladder Smooth Muscle Hypertrophy. <i>American Journal of Pathology</i> , 2019, 189, 847-867.	1.9	5
41	African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. <i>Journal of Urology</i> , 2019, 202, 247-255.	0.2	19
42	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity; Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. <i>Molecular Pharmaceutics</i> , 2018, 15, 1778-1790.	2.3	3
43	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. <i>JAMA Oncology</i> , 2018, 4, e175230.	3.4	65
44	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1402-1414.	3.2	34
45	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 182-189.	2.7	132
46	Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 409-415.	0.6	52
47	Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. <i>Journal of Cancer Education</i> , 2018, 33, 180-185.	0.6	14
48	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018, 73, 524-532.	0.9	60
49	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	0.9	54
50	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018, 74, 99-106.	0.9	28
51	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	29
52	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	0.8	155
53	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	0.8	162
54	SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 577-582.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	3.2	24
56	Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 605-611.	0.6	5
57	Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 342-347.	0.6	25
58	Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics. <i>Practical Radiation Oncology</i> , 2017, 7, 241-245.	1.1	4
59	Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. <i>Cancer</i> , 2017, 123, 2240-2247.	2.0	2
60	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e299-e309.	0.9	25
61	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 259-268.	2.3	14
62	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
63	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e25-542.e32.	0.8	6
64	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.	0.4	94
65	RB Loss Promotes Prostate Cancer Metastasis. <i>Cancer Research</i> , 2017, 77, 982-995.	0.4	67
66	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	3.2	87
67	Prognostic outlier genes for enhanced prostate cancer treatment. <i>Future Oncology</i> , 2017, 13, 249-261.	1.1	5
68	Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. <i>European Urology</i> , 2017, 71, 257-266.	0.9	59
69	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017, 197, 122-128.	0.2	33
70	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017, 8, 50804-50813.	0.8	29
71	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. <i>Journal of Clinical Oncology</i> , 2017, 35, 1982-1990.	0.8	76
72	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2017, 35, 1991-1998.	0.8	176

#	ARTICLE	IF	CITATIONS
73	<i>AXIN2</i> expression predicts prostate cancer recurrence and regulates invasion and tumor growth. <i>Prostate</i> , 2016, 76, 597-608.	1.2	14
74	Reply to Nicola Fossati, Giorgio Gandaglia, Alberto Bossi, Francesco Montorsi, Alberto Briganti's Letter to the Editor re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy After Radical Prostatectomy. <i>Eur Urol</i> 2016;70:588-96. <i>European Urology</i> , 2016, 70, e110-e111.	0.9	0
75	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. <i>Urology Case Reports</i> , 2016, 9, 51-54.	0.1	0
76	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy: A Multi-Institutional Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1046-1053.	0.4	47
77	ASTRO APEX and RO-ILS are applicable to medical malpractice in radiation oncology. <i>Future Oncology</i> , 2016, 12, 2643-2657.	1.1	5
78	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3648-3654.	0.8	296
79	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	5.1	182
80	The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 321-326.	0.6	7
81	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. <i>Cancer Research</i> , 2016, 76, 4948-4958.	0.4	147
82	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 683-690.	0.4	57
83	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2016, 76, 125-139.	1.2	17
84	Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. <i>European Urology</i> , 2016, 70, 588-596.	0.9	69
85	Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e282.	2.3	14
86	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.	3.4	46
87	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. <i>European Urology</i> , 2016, 70, 14-17.	0.9	79
88	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1777-1786.	3.2	42
89	A single activity with a practice quality improvement project for faculty and a quality improvement project for residents. <i>Practical Radiation Oncology</i> , 2016, 6, 114-118.	1.1	3
90	Quercetin regulates β -catenin signaling and reduces the migration of triple negative breast cancer. <i>Molecular Carcinogenesis</i> , 2016, 55, 743-756.	1.3	83

#	ARTICLE	IF	CITATIONS
91	Radioisotopes in management of metastatic prostate cancer. Indian Journal of Urology, 2016, 32, 277.	0.2	4
92	Radium-223 in Metastatic Castrate Resistant Prostate Cancer. , 2016, , 171-185.		0
93	Evaluating the Clinical Impact of a Genomic Classifier in Prostate Cancer Using Individualized Decision Analysis. PLoS ONE, 2015, 10, e0116866.	1.1	11
94	What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiotherapy and Oncology, 2015, 115, 295-300.	0.3	102
95	Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy. Journal of Clinical Oncology, 2015, 33, 944-951.	0.8	196
96	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology, 2015, 68, 555-567.	0.9	125
97	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell, 2015, 28, 97-113.	7.7	148
98	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2789-2796.	0.8	127
99	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. Clinical Cancer Research, 2015, 21, 795-807.	3.2	89
100	Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 55-60.	0.6	20
101	Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation. Journal of Nanobiotechnology, 2015, 13, 61.	4.2	23
102	Is robotic arm stereotactic body radiation therapy "virtual high-dose rate brachytherapy" effective for prostate cancer? An analysis of comparative effectiveness using published data. Expert Review of Medical Devices, 2015, 12, 317-327.	1.4	8
103	Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?. Expert Review of Anticancer Therapy, 2014, 14, 39-50.	1.1	14
104	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology, The, 2014, 15, 1469-1480.	5.1	226
105	Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. Journal of Contemporary Brachytherapy, 2014, 3, 262-270.	0.4	17
106	High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treatment Reviews, 2014, 40, 414-425.	3.4	57
107	AR function in promoting metastatic prostate cancer. Cancer and Metastasis Reviews, 2014, 33, 399-411.	2.7	73
108	Effect of docetaxel on safety and efficacy of radium-223. Lancet Oncology, The, 2014, 15, 1292-1293.	5.1	2

#	ARTICLE	IF	CITATIONS
109	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1038-1046.	0.4	149
110	Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. <i>Brachytherapy</i> , 2014, 13, 456-464.	0.2	6
111	The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness. <i>Clinical Cancer Research</i> , 2014, 20, 5468-5482.	3.2	19
112	A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. <i>Future Oncology</i> , 2014, 10, 457-474.	1.1	18
113	Practical guide to the use of radium 223 dichloride. <i>Canadian Journal of Urology</i> , 2014, 21, 70-6.	0.0	13
114	Evolution of advanced technologies in prostate cancer radiotherapy. <i>Nature Reviews Urology</i> , 2013, 10, 565-579.	1.9	61
115	The Dilemma of a Rising Prostate-Specific Antigen Level After Local Therapy: What Are Our Options?. <i>Seminars in Oncology</i> , 2013, 40, 322-336.	0.8	36
116	Multimodality Therapy for Patients With High-Risk Prostate Cancer: Current Status and Future Directions. <i>Seminars in Oncology</i> , 2013, 40, 308-321.	0.8	22
117	Phase I trials involving radiation therapy, quantifying the risks. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 719-724.	0.9	3
118	Impact of a Radiation Oncology Elective on the Careers of Young Physicians: Update on a Prospective Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 214-215.	0.4	11
119	Systematic review of hypofractionated radiation therapy for prostate cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 728-736.	3.4	56
120	The Responsibilities of a Chief Resident in Radiation Oncology: Results of a National Survey. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 460-461.	0.4	5
121	Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?. <i>Cancer Treatment Reviews</i> , 2013, 39, 212-218.	3.4	36
122	A Phase I Study of the Combination of Sorafenib With Temozolomide and Radiation Therapy for the Treatment of Primary and Recurrent High-Grade Gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 321-328.	0.4	41
123	Predictors of Radiation Oncology Resident Research Productivity. <i>Journal of the American College of Radiology</i> , 2013, 10, 185-189.	0.9	43
124	ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. <i>Future Oncology</i> , 2013, 9, 737-745.	1.1	25
125	Patterns of Care for Elderly Men Diagnosed With Favorable-risk Prostate Cancer From 2004 to 2008. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 606-611.	0.6	9
126	A Hormone-Independent DNA Repair Circuit Governs the Response to Genotoxic Insult. <i>Cancer Discovery</i> , 2013, 3, 1254-1271.	7.7	294

#	ARTICLE	IF	CITATIONS
127	Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. <i>Expert Review of Medical Devices</i> , 2013, 10, 751-763.	1.4	8
128	Commissioning and implementation of an implantable dosimeter for radiation therapy. <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 234-252.	0.8	4
129	mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, 1-12.	1.6	48
130	Heat shock protein 90 inhibition: rationale and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 211-218.	1.4	49
131	Combined Role of Whole-Brain Radiation Therapy and Radiosurgery for the Treatment of Brain Metastasis. <i>Progress in Neurological Surgery</i> , 2012, 25, 228-235.	1.3	6
132	Implanted Dosimeters Identify Radiation Overdoses During IMRT for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e371-e376.	0.4	13
133	Assessing the Value of an Optional Radiation Oncology Clinical Rotation During the Core Clerkships in Medical School. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e465-e469.	0.4	28
134	In Regard to Yeoh et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 4.	0.4	1
135	Salvage radiotherapy for prostate cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 1449-1453.	1.5	1
136	Radiotherapy for Brain Metastases. <i>Neurosurgery Clinics of North America</i> , 2011, 22, 37-44.	0.8	6
137	Postprostatectomy radiation therapy: an evidence-based review. <i>Future Oncology</i> , 2011, 7, 1429-1440.	1.1	12
138	Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2011, 8, 562-568.	1.9	39
139	Daily Image Guidance With Cone-Beam Computed Tomography for Head-and-Neck Cancer Intensity-Modulated Radiotherapy: A Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1353-1359.	0.4	123
140	Toward Dose Optimization for Fractionated Stereotactic Radiotherapy for Acoustic Neuromas: Comparison of Two Dose Cohorts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 419-426.	0.4	50
141	Influence of Radiotherapy Technique and Dose on Patterns of Failure for Mesothelioma Patients After Extrapleural Pneumonectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1366-1374.	0.4	56
142	DNA bending by asymmetrically tethered cations: influence of tether flexibility. <i>Chemistry and Biology</i> , 2001, 8, 967-980.	6.2	16
143	Relating Independent Measures of DNA Curvature: Electrophoretic Anomaly and Cyclization Efficiency. <i>Journal of Biomolecular Structure and Dynamics</i> , 2000, 18, 219-230.	2.0	11